Literature DB >> 26342235

Expansion platform type II: testing a treatment strategy.

Daniel V T Catenacci1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26342235      PMCID： PMC4987713          DOI： 10.1016/S1470-2045(15)00224-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Authors:  Ariel Lopez-Chavez; Anish Thomas; Arun Rajan; Mark Raffeld; Betsy Morrow; Ronan Kelly; Corey Allan Carter; Udayan Guha; Keith Killian; Christopher C Lau; Zied Abdullaev; Liqiang Xi; Svetlana Pack; Paul S Meltzer; Christopher L Corless; Alan Sandler; Carol Beadling; Andrea Warrick; David J Liewehr; Seth M Steinberg; Arlene Berman; Austin Doyle; Eva Szabo; Yisong Wang; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

Review 2.  National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

Authors:  Jeffrey Abrams; Barbara Conley; Margaret Mooney; James Zwiebel; Alice Chen; John J Welch; Naoko Takebe; Shakun Malik; Lisa McShane; Edward Korn; Mickey Williams; Louis Staudt; James Doroshow
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

3.  Next-generation companion diagnostics: promises, challenges, and solutions.

Authors:  Joseph D Khoury; Daniel V T Catenacci
Journal:  Arch Pathol Lab Med       Date:  2015-01       Impact factor: 5.534

4.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Authors:  Christophe Le Tourneau; Jean-Pierre Delord; Anthony Gonçalves; Céline Gavoille; Coraline Dubot; Nicolas Isambert; Mario Campone; Olivier Trédan; Marie-Ange Massiani; Cécile Mauborgne; Sebastien Armanet; Nicolas Servant; Ivan Bièche; Virginie Bernard; David Gentien; Pascal Jezequel; Valéry Attignon; Sandrine Boyault; Anne Vincent-Salomon; Vincent Servois; Marie-Paule Sablin; Maud Kamal; Xavier Paoletti
Journal:  Lancet Oncol       Date:  2015-09-03       Impact factor: 41.316

Review 5.  Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.

Authors:  Daniel V T Catenacci
Journal:  Mol Oncol       Date:  2014-10-18       Impact factor: 6.603

6.  Evaluating many treatments and biomarkers in oncology: a new design.

Authors:  Richard Kaplan; Timothy Maughan; Angela Crook; David Fisher; Richard Wilson; Louise Brown; Mahesh Parmar
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544
  6 in total
  6 in total

Review 1.  Precision medicine needs randomized clinical trials.

Authors:  Everardo D Saad; Xavier Paoletti; Tomasz Burzykowski; Marc Buyse
Journal:  Nat Rev Clin Oncol       Date:  2017-02-07       Impact factor: 66.675

Review 2.  Novel Targeted Therapies for Esophagogastric Cancer.

Authors:  Steven B Maron; Daniel V T Catenacci
Journal:  Surg Oncol Clin N Am       Date:  2017-04       Impact factor: 3.495

3.  Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma.

Authors:  Steven B Maron; Lindsay Alpert; Heewon A Kwak; Samantha Lomnicki; Leah Chase; David Xu; Emily O'Day; Rebecca J Nagy; Richard B Lanman; Fabiola Cecchi; Todd Hembrough; Alexa Schrock; John Hart; Shu-Yuan Xiao; Namrata Setia; Daniel V T Catenacci
Journal:  Cancer Discov       Date:  2018-02-15       Impact factor: 39.397

Review 4.  Clinical Trials in the Genomic Era.

Authors:  Erel Joffe; Alexia Iasonos; Anas Younes
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

5.  Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

Authors:  Eirini Pectasides; Matthew D Stachler; Sarah Derks; Yang Liu; Steven Maron; Adam J Bass; Daniel V Catenacci; Mirazul Islam; Lindsay Alpert; Heewon Kwak; Hedy Kindler; Blase Polite; Manish R Sharma; Kenisha Allen; Emily O'Day; Samantha Lomnicki; Melissa Maranto; Rajani Kanteti; Carrie Fitzpatrick; Christopher Weber; Namrata Setia; Shu-Yuan Xiao; John Hart; Rebecca J Nagy; Kyoung-Mee Kim; Min-Gew Choi; Byung-Hoon Min; Katie S Nason; Lea O'Keefe; Masayuki Watanabe; Hideo Baba; Rick Lanman; Agoston T Agoston; David J Oh; Andrew Dunford; Aaron R Thorner; Matthew D Ducar; Bruce M Wollison; Haley A Coleman; Yuan Ji; Mitchell C Posner; Kevin Roggin; Kiran Turaga; Paul Chang; Kyle Hogarth; Uzma Siddiqui; Andres Gelrud; Gavin Ha; Samuel S Freeman; Justin Rhoades; Sarah Reed; Greg Gydush; Denisse Rotem; Jon Davison; Yu Imamura; Viktor Adalsteinsson; Jeeyun Lee
Journal:  Cancer Discov       Date:  2017-10-04       Impact factor: 39.397

6.  Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.

Authors:  Daniel V T Catenacci; Stephanie Moya; Samantha Lomnicki; Leah M Chase; Bryan F Peterson; Natalie Reizine; Lindsay Alpert; Namrata Setia; Shu-Yuan Xiao; John Hart; Uzma D Siddiqui; D Kyle Hogarth; Oliver S Eng; Kiran Turaga; Kevin Roggin; Mitchell C Posner; Paul Chang; Sunil Narula; Murtuza Rampurwala; Yuan Ji; Theodore Karrison; Chih-Yi Liao; Blase N Polite; Hedy L Kindler
Journal:  Cancer Discov       Date:  2020-11-24       Impact factor: 39.397
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.